In the past decade, more than 25% of drug approvals were for treatment of cancer. Much can be learned from the regulatory pathways taken. Have regulatory initiatives to speed up the authorization of cancer drugs lived up to the expectations?
In RA2day, we evaluate regulatory performance and answer key questions. Is time to get to the market decreased? How is the regulatory toolbox used? What are the differences between EU and US? See how data from the Zwiers 2010-2020 oncology database substantiate the impact of regulatory affairs on approvals in general and for oncology drugs in particular.
But also…be prepared to expect the unexpected … .
Overview of a decade of new oncology drugs
Ready to learn more about the impact of Regulatory Affairs in the oncology field?
Join us in celebrating 10 years of solid RA/PV service!
Including lunch | Networking opportunity | €100 (ex VAT) fee for charity